Need pharma insights? Register for Evaluate Discovery
Menu
Menu
Screening and valuing pharma assets can be a thorny path, with so many data points to work through. Our solutions provide an accurate, impartial, and timely view of pharma asset potential. Forecast product-level risk, costs, and timelines to make key commercial decisions with confidence.
Check your assumptions, conduct deep due diligence, and assess the value of a potential target or your own portfolio with objectivity. Whether you are looking to expand your product pipelines or enter new markets, find out how our asset screening tools can inform your strategic decision-making.
Screen candidates for in-licencing and acquisition in your area of interest, quickly determining which have positive readouts and which raise red flags. Cross-check internal assumptions against the industry’s trusted consensus forecast to ensure all relevant data sources are considered.
Use our NPV Analyzer to identify projected sales, time to peak revenue, and costs. Unearth potential risks and opportunities for improvement, building actionable recommendations based on screening analysis to include in reporting.
Conduct detailed market analysis, understand macro trends, compare specific companies, and explore emerging spaces. Search for companies that are ready for funding or acquisition, identifying risk and commercial potential earlier in the screening process.
View current and forecasted financials, value R&D, and assess the worth of both marketed assets and pipelines by leveraging the unique connections between consensus forecasts and pipelines. Additionally, conduct scenario analysis for better decision-making.
Uncover unique and highly accurate insights into assets and commercial opportunities by analyzing risk and return correlations. This valuable information helps in screening assets and making informed decisions.
Accurately determine the commercial opportunities and the worth of potential assets through thorough scanning and assessment. This allows for the creation of a refined asset list and estimation of patient populations.
Know which opportunities and markets offer the highest growth potential. Focus your resources strategically.
Find and validate pharma opportunities with a robust assessment of market fit, risk, uptake and sales forecasts, and more.
Know which opportunities and markets offer the highest growth potential. Focus your resources strategically.
Build a better understanding of your growth drivers and product differentiators with a clear analysis of market dynamics, trends, unmet needs, and competitors.
Determine the true worth and potential of assets, score high-value opportunities, and make confident licensing or acquisition decisions.
Triangulate internal assumptions and power your allocation strategy with external benchmarking data across the R&D landscape.
Understand the context. Data-driven news and analysis for the pharma, biotech and medtech sectors.
If there’s one thing that the experts at Evaluate love, it’s rummaging around in data to identify trends in the pharma market. One area that is always fascinating to explore...
September 27, 2024
Volume is up but value is down. That’s the headline of the dealmaking scene for the first half of 2024. There’s not been a mega-merger in the vein of 2023’s...
August 8, 2024
Kelly Chamberlain may not have been at the company very long, but that didn’t stop me swooping in to find out a little more about her. Kelly has joined Norstella,...
If you missed our recent webinar, AI and ML in Pharma: Redefining the Forecasting Landscape, then I hope it’s because you were on a lovely vacation somewhere. Now that you’re...
July 24, 2024
There is no shortage of discussion about the opportunities presented by artificial intelligence and AI in the pharma industry. 50% of global healthcare companies plan to implement AI strategies by...
Evaluate’s annual World Preview report is a must-read for many in the pharma industry. Each year, we pull together some of our key pharma forecasts to build a picture of...
